Acadia Pharmaceuticals Reports Q3 2026 Revenue Growth Driven by DAYBUE and NUPLAZID
Acadia Pharmaceuticals (ACAD) reported strong third-quarter results for 2026, with total revenues reaching $342 million, a 22% increase year-over-year. The growth was primarily fueled by the performance of DAYBUE, which saw net sales of $140 million (up 39%), and NUPLAZID, which recorded $202 million in net sales (up 12%). Management raised annual guidance for DAYBUE following rapid adoption of its STIX formulation. Despite the commercial success, the company faced clinical headwinds as the Phase II RADIANT study for remlifanserin in Alzheimer's disease psychosis narrowly missed statistical significance on its primary endpoint. However, Acadia maintains a strong liquidity position with $976 million in cash and investments to support ongoing pipeline development and potential business acquisitions.
Tickers: $ACAD
Topics: Clinical Development Financial Guidance Product Sales Revenue Growth